Rani Therapeutics (RANI) Stock
Biotech company developing swallowable capsules for injectable drugs. Here's the price, business snapshot, and what's worth knowing about Rani Therapeutics in July 2026.
Rani Therapeutics (RANI) is a small-cap, clinical-stage biotechnology company developing an oral delivery platform for large-molecule therapeutics. With a market capitalisation around $205m, the business is centred on its RaniPill approach — a swallowable capsule designed to deliver biologic drugs without injections. Investors should know this is an early-stage story: most value hinges on clinical readouts, regulatory progress and potential partnerships or licensing deals. Revenues are currently limited and the company may need additional funding, which can dilute shareholders. The share price can be volatile and outcomes are binary around trial and approval milestones. This summary is for general educational purposes only and not personal investment advice. Consider your risk tolerance, investment horizon and seek regulated financial advice if unsure. Past performance or the promise of technology does not guarantee future returns; values can rise and fall.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Rani Therapeutics stock, indicating significant potential for price growth.
Financial Health
Rani Therapeutics is managing its expenses well and has decent cash generation for growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring RANI
Obesity Drug Pricing | Pharma Investment Theme
New agreements with Eli Lilly and Novo Nordisk are set to dramatically lower the cost of popular weight-loss drugs, making them accessible to millions through Medicare. This creates an investment opportunity centered on the major pharmaceutical companies involved and the broader supply chain that will support the expected surge in demand.
Published: 8 November 2025
Explore BasketWeight-Loss Drug M&A: Valuation Risk Concerns
Novo Nordisk's superior bid for Metsera has ignited a bidding war with Pfizer, highlighting the intense M&A activity in the obesity drug market. This theme focuses on other biotech companies with promising weight-loss therapies that could become the next acquisition targets.
Published: 31 October 2025
Explore BasketAt-Home Treatment Revolution | FDA Approval Impact
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.
Published: 1 September 2025
Explore BasketInjectable Drug Innovation Opportunities 2025
The FDA's approval of an at-home injectable version of Eisai and Biogen's Alzheimer's drug, Leqembi, simplifies treatment for patients and caregivers. This development highlights a growing trend toward patient-centric care, creating investment opportunities in companies that specialize in innovative drug delivery systems and at-home therapeutic technologies.
Published: 31 August 2025
Explore BasketBeyond The Needle: The Oral GLP-1 Revolution
Eli Lilly's successful trial of its oral weight-loss drug, orforglipron, signals a major shift in the treatment landscape for obesity and diabetes. This theme focuses on the innovative pharmaceutical companies developing the next wave of convenient, non-injectable therapies poised to challenge the dominance of current market leaders.
Published: 28 August 2025
Explore BasketNext-Generation Drug Delivery Systems
This carefully selected group of stocks represents innovative companies revolutionizing how medications are delivered to patients. Handpicked by our professional analysts, these firms are developing technologies that make treatments simpler, more effective, and user-friendly, creating meaningful investment potential in an evolving healthcare landscape.
Published: 18 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Oral biologics platform
Rani’s RaniPill aims to transform how large-molecule drugs are delivered, potentially expanding patient access — though outcomes depend on clinical success.
Clinical catalysts ahead
Trial readouts and regulatory milestones can materially affect valuation; these binary events drive volatility and present both upside and downside risks.
Partnership potential
Licensing or collaborations with pharma firms could accelerate commercialisation, yet deals are uncertain and may take time to materialise.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
